AU2020417892B2 - Insulin derivative - Google Patents

Insulin derivative

Info

Publication number
AU2020417892B2
AU2020417892B2 AU2020417892A AU2020417892A AU2020417892B2 AU 2020417892 B2 AU2020417892 B2 AU 2020417892B2 AU 2020417892 A AU2020417892 A AU 2020417892A AU 2020417892 A AU2020417892 A AU 2020417892A AU 2020417892 B2 AU2020417892 B2 AU 2020417892B2
Authority
AU
Australia
Prior art keywords
human insulin
desb30 human
γglu
eicosanedioyl
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020417892A
Other languages
English (en)
Other versions
AU2020417892A1 (en
Inventor
Lingyu CAI
Wei Chen
Zhongru Gan
Bin MU
Jianghong NIU
Fangkai XUE
Yining Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gan and Lee Pharmaceuticals Co Ltd
Original Assignee
Gan and Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gan and Lee Pharmaceuticals Co Ltd filed Critical Gan and Lee Pharmaceuticals Co Ltd
Publication of AU2020417892A1 publication Critical patent/AU2020417892A1/en
Application granted granted Critical
Publication of AU2020417892B2 publication Critical patent/AU2020417892B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2020417892A 2019-12-30 2020-12-29 Insulin derivative Active AU2020417892B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911398378.0 2019-12-30
CN201911398378 2019-12-30
CN202011057926 2020-09-29
CN202011057926.6 2020-09-29
PCT/CN2020/141023 WO2021136296A1 (zh) 2019-12-30 2020-12-29 胰岛素衍生物

Publications (2)

Publication Number Publication Date
AU2020417892A1 AU2020417892A1 (en) 2022-08-25
AU2020417892B2 true AU2020417892B2 (en) 2026-07-09

Family

ID=76687317

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020417892A Active AU2020417892B2 (en) 2019-12-30 2020-12-29 Insulin derivative
AU2020418205A Active AU2020418205B2 (en) 2019-12-30 2020-12-29 Insulin derivative

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020418205A Active AU2020418205B2 (en) 2019-12-30 2020-12-29 Insulin derivative

Country Status (10)

Country Link
US (5) US20240025957A1 (cg-RX-API-DMAC7.html)
EP (3) EP4086279A4 (cg-RX-API-DMAC7.html)
JP (3) JP2023510219A (cg-RX-API-DMAC7.html)
KR (2) KR20220121833A (cg-RX-API-DMAC7.html)
CN (12) CN118754967A (cg-RX-API-DMAC7.html)
AU (2) AU2020417892B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022013009A2 (cg-RX-API-DMAC7.html)
CA (2) CA3166495A1 (cg-RX-API-DMAC7.html)
MX (2) MX2022008130A (cg-RX-API-DMAC7.html)
WO (3) WO2021136302A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020418207A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
BR112022013009A2 (pt) * 2019-12-30 2022-09-06 Gan & Lee Pharmaceuticals Co Ltd Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3217734A1 (en) * 2021-05-24 2022-12-01 Baoye ZHENG A novel acylated insulin analog
WO2022268208A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 含酰化胰岛素的药物组合物
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
WO2023143458A1 (zh) * 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素
CN117586376A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效胰岛素化合物
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
JP2026517987A (ja) * 2023-05-24 2026-06-02 ザ ユナイテッド バイオテクノロジー(ヘンチン)シーオー.,エルティーディー. インスリン誘導体およびその使用
CN116327890B (zh) * 2023-05-29 2023-12-08 北京先为达生物科技有限公司 口服递送的组合物及其应用
CN116789801B (zh) * 2023-08-21 2023-11-14 南京赛诺生物技术有限公司 新型胰岛素衍生物及其用途
AU2024358560A1 (en) * 2023-10-09 2026-05-14 Gan & Lee Pharmaceuticals Co., Ltd. Glp -1 peptide composition and use thereof
WO2025098457A1 (zh) 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
CN122555570A (zh) * 2023-11-08 2026-08-11 甘李药业股份有限公司 包含胰岛素衍生物的药物组合物的治疗用途
WO2025228255A1 (zh) * 2024-04-28 2025-11-06 正大天晴药业集团股份有限公司 酰化人胰岛素类似物
CN120887973A (zh) * 2024-06-13 2025-11-04 惠升生物制药股份有限公司 一种长效酰化胰岛素衍生物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105720A1 (en) * 2008-03-13 2011-05-05 Peter Madsen Protease stabilized, acylated insulin analogues
WO2016119854A1 (en) * 2015-01-29 2016-08-04 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating
US9481721B2 (en) * 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
WO2017032798A1 (en) * 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
NZ273285A (en) 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
IL118127A0 (en) 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
JP5202338B2 (ja) * 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー/エス 新規インシュリン誘導体
AU2007247109B2 (en) 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
EP2170945A1 (en) 2007-07-16 2010-04-07 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
WO2009022006A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
CN102149411A (zh) * 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
BR112012016853A2 (pt) * 2010-01-12 2017-10-17 Novo Nordisk As "composições farmacêuticas para administração oral de peptídeos de insulina".
KR20130018410A (ko) 2010-03-26 2013-02-21 노보 노르디스크 에이/에스 새로운 글루카곤 유사체
EP2720711A1 (en) * 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
CN104788556A (zh) 2011-12-15 2015-07-22 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ, エルエルシー 細胞外標的化薬物共役体
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN105820233B (zh) 2015-01-04 2021-06-15 甘李药业股份有限公司 一种胰岛素衍生物的制备方法
EP3341401A1 (en) * 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3341991B1 (en) * 2015-08-27 2020-07-08 Haldor Topsøe A/S High tap density lithium positive electrode active material, intermediate and process of preparation
US10815287B2 (en) 2016-08-02 2020-10-27 Jiangsu Hengrui Medicine Co., Ltd. Acylated derivative of human insulin or analogue thereof
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
AU2020418207A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
BR112022013009A2 (pt) * 2019-12-30 2022-09-06 Gan & Lee Pharmaceuticals Co Ltd Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
WO2023143458A1 (zh) * 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105720A1 (en) * 2008-03-13 2011-05-05 Peter Madsen Protease stabilized, acylated insulin analogues
US9481721B2 (en) * 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
WO2016119854A1 (en) * 2015-01-29 2016-08-04 Novo Nordisk A/S Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating
WO2017032798A1 (en) * 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kurtzhals, P., et al. "Albumin binding of insulins acylated with fatty acids: charact. of the ligand-protein interact. and correl. between binding affinity and timing of the Ins. effect in vivo." Biochemical Journal 312.3 (1995): 725-731. *

Also Published As

Publication number Publication date
CN114901681B (zh) 2024-04-09
WO2021136302A1 (zh) 2021-07-08
CA3166494A1 (en) 2021-07-08
CN118598978A (zh) 2024-09-06
US20250032589A1 (en) 2025-01-30
EP4086279A4 (en) 2024-08-07
US12576136B2 (en) 2026-03-17
CN118894922A (zh) 2024-11-05
BR112022013150A2 (pt) 2023-02-28
EP4086278A4 (en) 2024-08-07
WO2021136296A1 (zh) 2021-07-08
WO2021136293A1 (zh) 2021-07-08
JP2023510219A (ja) 2023-03-13
US20250228919A1 (en) 2025-07-17
MX2022008130A (es) 2022-10-03
CN114901681A (zh) 2022-08-12
CN114901683A (zh) 2022-08-12
KR20220119730A (ko) 2022-08-30
EP4086280A1 (en) 2022-11-09
EP4086279A1 (en) 2022-11-09
EP4086278A1 (en) 2022-11-09
CN114901682A (zh) 2022-08-12
CN118420744A (zh) 2024-08-02
CA3166495A1 (en) 2021-07-08
MX2022008174A (es) 2022-08-02
US20230126068A1 (en) 2023-04-27
US20240239862A1 (en) 2024-07-18
CN118754967A (zh) 2024-10-11
BR112022013009A2 (pt) 2022-09-06
EP4086280A4 (en) 2024-05-29
CN118480114A (zh) 2024-08-13
KR20220121833A (ko) 2022-09-01
US20240025957A1 (en) 2024-01-25
CN118666989A (zh) 2024-09-20
CN114901683B (zh) 2024-09-13
CN118772259A (zh) 2024-10-15
AU2020417892A1 (en) 2022-08-25
CN114901682B (zh) 2024-04-16
AU2020418205B2 (en) 2026-07-30
JP2025161829A (ja) 2025-10-24
CN118420743A (zh) 2024-08-02
CN118206632A (zh) 2024-06-18
AU2020418205A1 (en) 2022-08-04
JP2023510206A (ja) 2023-03-13